Effect of Anti-B16 Melanoma Monoclonal Antibody on Established Murine B16 Melanoma Liver Metastases

Avi Eisenthal, Rene Lafreniere, Alan T. Lefor, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The administration of anti-B16 monoclonal antibody of the IgG2b isotype to mice bearing established B16 melanoma liver metastases caused a significant and consistent reduction of up to 90% in the number of these metastases. No reduction in the number of metastases was noted when antigenically unrelated tumor or nonspecific immunoglobulin were employed. The antibody-mediated antitumor effect was completely abrogated by total body irradiation of the host. Treatment of the tumor-bearing host with antiserum directed against asialo Gm1Prior to anti B16 antibody administration, abrogated the therapeutic effect indicating the involvement of a radiosensitive, ASGM1-positive cell in the tumor regression. The antitumor effect of the antibody treatment could be augmented by the concomitant administration of recombinant interleukin-2. The effect seen may have possible application in the treatment of liver metastases in humans by combined immunotherapy using recombinant interleukin-2 and specific antitumor monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)2771-2776
Number of pages6
JournalCancer Research
Volume47
Issue number11
StatePublished - Jun 1 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effect of Anti-B16 Melanoma Monoclonal Antibody on Established Murine B16 Melanoma Liver Metastases'. Together they form a unique fingerprint.

  • Cite this

    Eisenthal, A., Lafreniere, R., Lefor, A. T., & Rosenberg, S. A. (1987). Effect of Anti-B16 Melanoma Monoclonal Antibody on Established Murine B16 Melanoma Liver Metastases. Cancer Research, 47(11), 2771-2776.